Compounds > citric acid, anhydrous
Page last updated: 2024-10-17

citric acid, anhydrous and Abdominal Pain

citric acid, anhydrous has been researched along with Abdominal Pain in 4 studies

Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.

Abdominal Pain: Sensation of discomfort, distress, or agony in the abdominal region.

Research Excerpts

ExcerptRelevanceReference
"All three preparations were equally well tolerated with slightly more diarrhea reported among patients receiving magnesium citrate (p = 0."5.08A randomized trial comparing three methods of bowel preparation for flexible sigmoidoscopy. ( Jackson, JL; Osgard, E; Strong, J, 1998)
"Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients."2.82The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain. ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yoshioka, S1
Takedatsu, H1
Fukunaga, S1
Kuwaki, K1
Yamasaki, H1
Yamauchi, R1
Mori, A1
Kawano, H1
Yanagi, T1
Mizuochi, T1
Ushijima, K1
Mitsuyama, K1
Tsuruta, O1
Torimura, T1
Freedman, SB1
Thull-Freedman, J1
Rumantir, M1
Eltorki, M1
Schuh, S1
Al-Saber, F1
Aldosari, W1
Alselaiti, M1
Khalfan, H1
Kaladari, A1
Khan, G1
Harb, G1
Rehani, R1
Kudo, S1
Koda, A1
Tanaka, T1
Nakajima, M1
Darwish, A1
Osgard, E1
Jackson, JL1
Strong, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes[NCT02481141]53 participants (Actual)Interventional2014-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in 2 Hour Post Meal Glucose Level

Change from baseline in blood glucose levels 2 hours after breakfast (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline-12.9
5-ALA-SFC Through Week 12 (100 mg 2x/Day) Change From Baseline-8.5
Placebo Through Week 2 Change From Baseline-26.5
Placebo Through Week 4 Change From Baseline-18.8
Placebo Through Week 12 Change From Baseline-33.0

Change From Baseline in Body Weight

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionkg (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-0.1
5-ALA-SFC Through Week 12 Change From Baseline-0.2
Placebo Through Week 6 Change From Baseline-0.3
Placebo Through Week 12 Change From Baseline-0.8

Change From Baseline in Fasting Blood Glucose

The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline2.3
5-ALA-SFC Through Week 4 (75 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through Wk 12 (100 mg 2x/Day) Change From Baseline-3.0
Placebo Through Week 2 Change From Baseline-7.3
Placebo Through Week 4 Change From Baseline-0.8
Placebo Through Week 12 Change From Baseline-4.2

Change From Baseline in HbA1c

Change from baseline in HbA1c % (NCT02481141)
Timeframe: Baseline, Week 2, Week 4, Week 12

Interventionpercentage of HbA1c (Mean)
5-ALA-SFC Through Week 2 (50 mg 2x/Day) Change From Baseline-0.2
5-ALA-SFC Through 4 (75 mg 2x/Day) Change From Baseline-0.3
5-ALA-SFC Through 12 (100 mg 2x/Day) Change From Baseline-0.7
Placebo Through Week 2 Change From Baseline-0.5
Placebo Through Week 4 Change From Baseline-0.5
Placebo Through Week 12 Change From Baseline-0.5

Change From Baseline in HDL (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-0.8
5-ALA-SFC Through Week 12 Change From Baseline0.5
Placebo Through Week 6 Change From Baseline-1.6
Placebo Through Week 12 Change From Baseline-1.1

Change From Baseline in Total Cholesterol (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-5.2
5-ALA-SFC Through Week 12 Change From Baseline6.8
Placebo Through Week 6 Change From Baseline-7.6
Placebo Through Week 12 Change From Baseline-0.1

Change From Baseline in Triglycerides (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-1.3
5-ALA-SFC Through Week 12 Change From Baseline3.2
Placebo Through Week 6 Change From Baseline4.5
Placebo Through Week 12 Change From Baseline11.9

Change From Baseline LDL (Component of Lipid Profile)

Change from baseline measured at week 6 and week 12 only (NCT02481141)
Timeframe: Baseline, Week 6, Week 12

Interventionmg/dL (Mean)
5-ALA-SFC Through Week 6 Change From Baseline-2.9
5-ALA-SFC Through Week 12 Change From Baseline7.6
Placebo Through Week 6 Change From Baseline-11.8
Placebo Through Week 12 Change From Baseline-4.0

Subjects With Adverse Events as a Measure of Safety and Tolerability

The objective of the current study was to investigate the safety and preliminary efficacy of doses up to 200 mg 5-ALA - SFC in a population of patients with type 2 diabetes mellitus living in Bahrain. (NCT02481141)
Timeframe: Week 2, Week 4, Week 12

InterventionParticipants (Count of Participants)
5-ALA-SFC Through Week 2 (50 mg 2x/Day)6
5-ALA-SFC Through Week 4 (75 mg 2x/Day)8
5-ALA-SFC Through Week 12 (100 mg 2x/Day)2
Placebo Through Week 23
Placebo Through Week 41
Placebo Through Week 121

Trials

2 trials available for citric acid, anhydrous and Abdominal Pain

ArticleYear
The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Abdominal Pain; Aminolevulinic Acid; Bahrain; Blood Glucose; Citric Acid; Cough; Diabetes Mellitus,

2016
A randomized trial comparing three methods of bowel preparation for flexible sigmoidoscopy.
    The American journal of gastroenterology, 1998, Volume: 93, Issue:7

    Topics: Abdominal Pain; Administration, Oral; Adult; Aged; Ambulatory Care; Cathartics; Citric Acid; Colon;

1998

Other Studies

2 other studies available for citric acid, anhydrous and Abdominal Pain

ArticleYear
Study to determine guidelines for pediatric colonoscopy.
    World journal of gastroenterology, 2017, Aug-21, Volume: 23, Issue:31

    Topics: Abdominal Pain; Adolescent; Age Factors; Cathartics; Child; Child, Preschool; Citric Acid; Colon; Co

2017
Pediatric constipation in the emergency department: evaluation, treatment, and outcomes.
    Journal of pediatric gastroenterology and nutrition, 2014, Volume: 59, Issue:3

    Topics: Abdominal Pain; Child; Child, Preschool; Citric Acid; Constipation; Diagnostic Imaging; Emergency Se

2014